If your child has excess weight, you have probably seen the headlines about GLP-1 medicines. Many parents now ask their pediatrician whether GLP-1 for kids is a realistic option, and the honest answer is that it depends on the product, the age, the country, and the child. This guide walks through what the WHO guideline does and does not say, what the trials measured, which risks the labels describe, and the questions to bring to the appointment. It does not replace a conversation with your child's doctor.
Parents are asking whether GLP-1 medicines could help their child. Here is what the WHO guideline, the pediatric trials, and the labels actually support, and the questions to bring to the clinic.
Why this question keeps showing up in clinics
Childhood obesity is a public health issue, and the WHO publishes prevalence estimates through its Global Health Observatory. Check the current figures there before you quote any number, because the data get updated.
GLP-1 medicines copy a gut hormone that slows stomach emptying and signals fullness to the brain. Semaglutide and liraglutide belong to close but not identical classes. Tirzepatide is a different case, since it acts on both GIP and GLP-1 receptors, which makes it a dual agonist. If you want background on how these molecules relate to other peptides, PeptPro's reference pages are a sensible place to read before the appointment. Wait, that link belongs later, so keep reading.
Sigue el nivel estimado de cada dosis y sabe cuándo aplicar.
Verlo en la appWhat the WHO guideline actually says, and what it does not
The WHO published its guideline on GLP-1 therapies for obesity in December 2025. Before you rely on any summary, this one included, open the document on the WHO website. Read the recommendation itself, note whether it is conditional or strong, and find the section on children and adolescents. This post does not reproduce the pediatric wording, so read those sentences directly instead of trusting a secondhand quote.
Three things get mixed up all the time. A guideline recommendation is what a health body suggests to clinicians and health systems. A regulatory approval is a decision by an agency such as the FDA, the EMA, or ANVISA that a product can be marketed for a given use and age group. The label, or prescribing information, lists the approved indication, the dosing, and the warnings. A guideline can speak to adults while saying little about children, and a product can be approved for teenagers in one country and not another. Each of these carries a different level of evidence.
The WHO frames these medicines as one part of broader care, alongside diet, physical activity, behavior support, and regular follow-up. They are not presented as a stand-alone fix, and that framing matters for how you think about a prescription for a child.
